These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 27000270)

  • 41. Legislation would put drugs and other therapies to a useful test.
    Carroll J
    Manag Care; 2008 May; 17(5):12-3. PubMed ID: 18567462
    [No Abstract]   [Full Text] [Related]  

  • 42. New drugs and indications in 2012. Sluggish progress, timid measures to protect patients.
    Prescrire Int; 2013 Apr; 22(137):105-7. PubMed ID: 23662323
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Technology and health reform: a legislative perspective.
    Durenberger DF; Foote SB
    Health Aff (Millwood); 1994; 13(3):197-205. PubMed ID: 7927150
    [No Abstract]   [Full Text] [Related]  

  • 44. Regulatory watch: impact of PDUFA on regulatory decision-making.
    Hay M
    Nat Rev Drug Discov; 2010 Aug; 9(8):585. PubMed ID: 20671755
    [No Abstract]   [Full Text] [Related]  

  • 45. [The health care structure law as a political public health reform in ambulatory and day surgery].
    Sorgatz H
    Zentralbl Chir; 1994; 119(7):455-9. PubMed ID: 7941791
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The response to health care reform by the pharmaceutical industry.
    Krulwich AS
    Food Drug Law J; 1995; 50(1):1-22. PubMed ID: 10342983
    [No Abstract]   [Full Text] [Related]  

  • 47. [Neither excess nor deficiency. Debate on a draft law on the reform of the legal health insurance - "Healthcare Reform 2000" during the 49th session of the Bundestag, June 30, 1999].
    Schaich-Walch G
    Internist (Berl); 1999 Sep; 40(9):M269-71. PubMed ID: 10506349
    [No Abstract]   [Full Text] [Related]  

  • 48. The issue of applying marketing on the pharmaceutical market in Serbia.
    Dickov V; Dickov A; Martinović-Mitrović S
    Eur Rev Med Pharmacol Sci; 2011 Mar; 15(3):275-83. PubMed ID: 21528773
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Supply legal and regulatory structure for restructuring the drug market].
    Dierks C
    Onkologie; 2013; 36 Suppl 4():12. PubMed ID: 23797365
    [No Abstract]   [Full Text] [Related]  

  • 50. Price and quality transparency: how effective for health care reform?
    Nyman JA; Li CH
    Minn Med; 2009 Jul; 92(7):32-5. PubMed ID: 19708312
    [TBL] [Abstract][Full Text] [Related]  

  • 51. ["Hard landing" due to inflexible fee system, but: "The market forces will increase quality in clinics". F&W compass comparison points to overmanagement of mild and undermanagement of severe cases].
    Lauterbach KW
    Chirurg; 2003 Feb; 74(2):M40. PubMed ID: 12691059
    [No Abstract]   [Full Text] [Related]  

  • 52. Impact of the new US health-care-reform legislation on the pharmaceutical industry: who are the real winners?
    Milne CP; Kaitin KI
    Clin Pharmacol Ther; 2010 Nov; 88(5):589-92. PubMed ID: 20959844
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Health care reform: taking focus.
    Murkowski FH
    Alaska Med; 1994; 36(2):114, 126. PubMed ID: 7943622
    [No Abstract]   [Full Text] [Related]  

  • 54. Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.
    Gitter DM
    Seton Hall Law Rev; 2011; 41(2):559-92. PubMed ID: 21739759
    [No Abstract]   [Full Text] [Related]  

  • 55. Health care reform. The implications for quality, risk & cost management.
    QRC Advis; 1994 Jan; 10(3):4-6. PubMed ID: 10131409
    [No Abstract]   [Full Text] [Related]  

  • 56. Pharmaceuticals and medical devices: cost savings. Issue brief.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-33. PubMed ID: 23297446
    [No Abstract]   [Full Text] [Related]  

  • 57. Industry and regulatory performance in 2012: a year in review.
    Dowden HM; Jahn R; Catka T; Jonsson A; Michael E; Miwa Y; Zinkand W
    Clin Pharmacol Ther; 2013 Sep; 94(3):359-66. PubMed ID: 23657160
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Lack of sensitivity to privacy. Debate on a draft law on the reform of the legal health insurance - "Healthcare Reform 2000" during the 49th session of the Bundestag, June 30, 1999].
    Parr D
    Internist (Berl); 1999 Sep; 40(9):M274-5. PubMed ID: 10506352
    [No Abstract]   [Full Text] [Related]  

  • 59. Paying for drug approvals--who's using whom?
    Avorn J
    N Engl J Med; 2007 Apr; 356(17):1697-700. PubMed ID: 17435083
    [No Abstract]   [Full Text] [Related]  

  • 60. Ode to Simeon, a highland seaman.
    Christy JP
    Mo Med; 2009; 106(6):400-1. PubMed ID: 20063506
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.